Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/47721
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Clavo, Bernardino | en_US |
dc.contributor.author | Santana Rodríguez, Norberto | en_US |
dc.contributor.author | Gutierrez, Dominga | en_US |
dc.contributor.author | Lopez, Juan C. | en_US |
dc.contributor.author | Suarez, Gerardo | en_US |
dc.contributor.author | López Ríos,Laura | en_US |
dc.contributor.author | Robaina, Francisco | en_US |
dc.contributor.author | Bocci, Velio | en_US |
dc.date.accessioned | 2018-11-23T15:52:02Z | - |
dc.date.available | 2018-11-23T15:52:02Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.issn | 1075-5535 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/47721 | - |
dc.description.abstract | Background: Headache afflicts approximately 10%-15% of the general population. Mixed results are obtained from various therapies, usually drugs, but also oxygen inhalation, behavioral psychology, physical therapy, and peripheral or central neurostimulation. When refractory to treatment, it has severe impact on quality of life. OBJECTIVES/SUBJECTS: Five (5) patients are presented who had suffered from severe/persistent headache refractory to standard management (including 5-HT1 agonist triptan drugs) and were treated with ozone therapy. Interventions: Ozone administration was by major autohemotherapy. The procedure involved venous blood drawn into a sterile single-use glass bottle containing anticoagulant, gently mixed with an equal volume of O3/O2 gas mixture (prefiltered through a sterile 0.20-μm filter) and slowly reinfused back into the donor patient via the antecubital vein. Outcome measures: The analyzed parameters were analgesia requirements, days of sick leave due to headache, number of headache events, and pain intensity according to the visual analogue scale (VAS); these recorded at three time points: pre-ozone therapy, post-ozone therapy, and before the last follow-up (mean: 64.6±36.8 months). Results: The number of headache episodes pretreatment (n=80; range 5-200) was significantly decreased during the first 6 months post-treatment (n=0, range 0-1; p=0.042) and over the 6 months before the last follow-up visit (n=1, range 0-2; p=0.043). The corresponding VAS scores were 8.7±0.8 pretreatment versus 1.1±2.5 the 6 months post-treatment (p=0.003) and versus 3.1±3.3 the 6 months before last follow-up visit (p=0.036). Conclusions: Ozone therapy decreased headache episodes and pain severity over a protracted period. This novel approach is effective and merits further research. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Journal of Alternative and Complementary Medicine | en_US |
dc.source | Journal of Alternative and Complementary Medicine[ISSN 1075-5535],v. 19, p. 453-458 (Mayo 2013) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3201 Ciencias clínicas | en_US |
dc.subject.other | Ozone therapy | en_US |
dc.subject.other | Headache | en_US |
dc.title | Long-term improvement in refractory headache following ozone therapy | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1089/acm.2012.0273 | en_US |
dc.identifier.scopus | 2-s2.0-84877313943 | - |
dc.contributor.authorscopusid | 57190093030 | - |
dc.contributor.authorscopusid | 56072780900 | - |
dc.contributor.authorscopusid | 8616778800 | - |
dc.contributor.authorscopusid | 55989423900 | - |
dc.contributor.authorscopusid | 7101855600 | - |
dc.contributor.authorscopusid | 56243678000 | - |
dc.contributor.authorscopusid | 6603449723 | - |
dc.contributor.authorscopusid | 7103297359 | - |
dc.description.lastpage | 458 | en_US |
dc.description.firstpage | 453 | en_US |
dc.relation.volume | 19 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 6 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Mayo 2013 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,499 | - |
dc.description.jcr | 1,518 | - |
dc.description.sjrq | Q1 | - |
dc.description.jcrq | Q2 | - |
dc.description.scie | SCIE | - |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.orcid | 0000-0003-2522-1064 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Clavo Varas,Bernardino | - |
crisitem.author.fullName | Santana Rodríguez,Norberto | - |
crisitem.author.fullName | López Ríos,Laura | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
20
checked on Nov 17, 2024
WEB OF SCIENCETM
Citations
21
checked on Nov 17, 2024
Page view(s)
48
checked on Jul 20, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.